News and Announcements
Warburton Global Fund promise fund will bounce back after October losses
- Published November 06, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Series 1 units of the Warburton Global Fund returned -23.9% in October.
- October saw significant decreases across the board and the Warburton Global Fund could not avoid negative return in this month.
- The majority of losses were from equities (-17.7%), with fixed income (-4.9%) and commodities (-3.5%) making up the remainder.
- The Warburton Global Fund made a modest profit from their currency book (+2.2%).
Series 1 units of the Warburton Global Fund returned an unavoidable -23.9% in October. The value of $1 invested since inception is $1.61.
October saw significant decreases across the board and the Warburton Global Fund could not avoid negative return in this month.
Equities were down in a lot of geographies and falls in energy and industrial metals outweighed the gains in precious metals.
The majority of losses were from equities (-17.7%), with fixed income (-4.9%) and commodities (-3.5%) making up the remainder.
Warburton Global Fund managers state that the fall in asset classes will not persist. Long-term investors will understand that the fund has historically bounced back.
About Warburton Investment Management
Warburton Investment Management manages client capital via the Warburton Global Fund, a global macro hedge fund that deals in international investments. The fund invests in public equity, fixed income, currency and commodity markets worldwide.
Founded in 2015, Warburton Investment Management is one of the best performing firms in the hedge fund industry, with a mandate to target annualised returns of over 30%.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
